Formula I Organic Compounds for Phosphorylated AMPK Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to effectively increase the level of phosphorylated AMP-activated protein kinase (AMPK) within cells, which is crucial for cellular energy homeostasis and metabolic regulation, particularly in conditions like cardiac ischemia/reperfusion and hypertrophy.
Innovation Solution
Development of organic compounds that can increase the level of phosphorylated AMPK within cells by administering specific compounds, such as those described by Formula (I), or their pharmaceutically acceptable salts, to enhance cellular AMPK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to increase phosphorylated AMPK levels, then cellular energy homeostasis should be improved, but the methods fail to effectively increase phosphorylated AMPK levels
Solution Approach 1:
The patent employs parameter changes by systematically varying chemical structures of compounds (Formula I with different R1, L1, X, L2, R2, R3 substituents) to optimize AMPK activation. This includes modifying molecular weight, lipophilicity, and functional groups to enhance phosphorylated AMPK levels while maintaining reliability of the effect.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to activate AMPK indirectly. These compounds (Formula I derivatives) serve as mediators that bind to AMPK or its regulatory pathways, triggering phosphorylation and activation without directly being the kinase itself, thus resolving the contradiction between effectiveness and reliability.
2Reliability
If compounds of Formula (I) are administered to increase phosphorylated AMPK levels, then therapeutic benefits for metabolic disorders should be achieved, but the complexity of compound synthesis and formulation increases
Solution Approach 1:
The patent segments the complex molecular structure of Formula I into modular components (R1, L1, X, L2, R2, R3 groups) that can be independently synthesized and assembled. This modular approach simplifies the overall synthesis complexity while maintaining the therapeutic effectiveness for metabolic disorders through systematic structure-activity relationship optimization.
Solution Approach 2:
The patent applies parameter changes by optimizing specific molecular parameters (substituent types, positions, and configurations in Formula I) to achieve the desired therapeutic effect. By systematically varying these parameters, the patent reduces synthesis complexity through identifying key structural features while maintaining reliability of therapeutic benefits.
3Productivity
If compounds are designed to specifically target AMPK activation, then metabolic regulation should be enhanced, but the specificity and selectivity of compound action may reduce
Solution Approach 1:
The patent applies local quality by designing specific regions in Formula I compounds (such as R1 heteroaryl groups, L1-L2 linkers, and R2-R3 substituents) with distinct functional properties. Different parts of the molecule interact with specific AMPK binding sites or regulatory elements, enhancing metabolic regulation while maintaining compound specificity through localized structural features.
Solution Approach 2:
The patent uses Formula I compounds as selective intermediaries that specifically target AMPK activation pathways. These compounds act as mediators with designed molecular features that preferentially bind to AMPK or its upstream regulators, enhancing metabolic regulation productivity while maintaining reliability of specificity through structure-activity relationship optimization.
Data Source
AI summary
This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for increasing the level of phosphorylated AMPK within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in the level of phosphorylated AMPK are provided.